Loading
  • Pipeline Pipeline
    • Pipeline Chart
    • Validive
      • Overview
      • Severe Oral Mucositis and Oropharyngeal Cancer
      • Phase 2 Data Supports Further Development in OPC
      • MNPR-301-001 Clinical Trial
    • Camsirubicin
      • Overview
      • Clinical Data
      • Development Strategy
      • MNPR-201-001 Clinical Trial
    • MNPR-101 RIT
    • MNPR-101
      • Overview
      • Development Strategy
    • MNPR-202
    • Collaborations
      • Overview
      • Current Collaborations
    • Intellectual Property
    • Publications
      • Validive
      • Camsirubicin
      • MNPR-101
  • Investors Investors
    • Overview
    • Annual Meeting
    • News / Events
      • Press Releases
      • IR Calendar
      • In the News
      • Email Alerts
    • Company Information
      • Profile
      • Presentations
      • Our Team
      • FAQ
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Our Team Our Team
  • Contact Us Contact Us
  • SIV Materials SIV Materials
  • Home
  • Investors
  • News / Events
  • Press Releases
Investors

Investors

  • Overview
  • Annual Meeting
  • News / Events
    • Press Releases
    • IR Calendar
    • In the News
    • Email Alerts
  • Company Info
    • Profile
    • Presentations
    • Our Team
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Press Releases
  • IR Calendar
  • In the News
  • Email Alerts

Press Releases

Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe

Sep 13, 2021

Monopar Therapeutics to Present at Upcoming Investor Conferences in September

Sep 9, 2021

Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates

Aug 12, 2021

Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial

Aug 5, 2021

Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma

Aug 3, 2021

Monopar Appoints Octávio Costa, MD, as Chief Medical Officer

Jul 12, 2021

Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO

Jun 24, 2021

Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer

Jun 3, 2021

Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer

Jun 1, 2021

Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic

May 26, 2021
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • About
    • Pipeline
    • Investors
    • Our Team
    • Contact Us
    • SIV Materials
    • Pipeline
    • Pipeline Chart
    • Validive
    • Camsirubicin
    • MNPR-101 RIT
    • MNPR-101
    • MNPR-202
    • Collaborations
    • Intellectual Property
    • Publications
    • Investors
    • Overview
    • Annual Meeting
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance

    Terms and Conditions of Use

    © 2023 Monopar Therapeutics Inc. All Rights Reserved.